<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40952750</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e253373</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2025.3373</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">The Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson's Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Bilateral STN-DBS for moderate to advanced PD.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P&#x2009;&lt;&#x2009;.001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P&#x2009;&lt;&#x2009;.001). Activities of daily living without medication as measured by UPDRS-III improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P&#x2009;&lt;&#x2009;.001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P&#x2009;&lt;&#x2009;.001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P&#x2009;&lt;&#x2009;.001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P&#x2009;&lt;&#x2009;.001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P&#x2009;&lt;&#x2009;.001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>Philip A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shivacharan</LastName><ForeName>Rajat S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Division of Neuromodulation, Boston Scientific, Valencia, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Neuromodulation, Boston Scientific, Valencia, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tr&#xf6;ster</LastName><ForeName>Alexander I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuropsychology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>House</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Neurosurgical Associates LLC, Murray, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giroux</LastName><ForeName>Monique L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Movement and Neuroperformance Center of Colorado, Englewood.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Clinical Lead Movement Disorders, Praxis Precision Medicines Inc, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hebb</LastName><ForeName>Adam O</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Kaiser Permanente, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whiting</LastName><ForeName>Donald M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leichliter</LastName><ForeName>Timothy A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Allegheny Health Network, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrem</LastName><ForeName>Jill L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metman</LastName><ForeName>Leo Verhagen</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sani</LastName><ForeName>Sepehr</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karl</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Mustafa S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatter</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haq</LastName><ForeName>Ihtsham Ul</ForeName><Initials>IU</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Andre G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Center for Neurological Restoration Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gostkowski</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neurological Restoration Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliati</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mamelak</LastName><ForeName>Adam N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foote</LastName><ForeName>Kelly D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, College of Medicine, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moguel-Cobos</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponce</LastName><ForeName>Francisco A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buetefisch</LastName><ForeName>Cathrin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurosurgery, Rutgers University Robert Wood Johnson Medical School, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luca</LastName><ForeName>Corneliu C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagid</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revuelta</LastName><ForeName>Gonzalo J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takacs</LastName><ForeName>Istvan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourfar</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University Medical Center, New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogilner</LastName><ForeName>Alon Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, New York University Medical Center, New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duker</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Cincinnati Medical Center, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandybur</LastName><ForeName>George T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Cincinnati Medical Center, Cincinnati, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurosurgery, Lee Health, Fort Myers, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenow</LastName><ForeName>Joshua M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Northwestern University School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zadikoff</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khandhar</LastName><ForeName>Suketu M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kaiser Permanente Medical Center, Sacramento, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedrak</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Neuroscience, Kaiser Permanente Medical Center, Redwood City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phibbs</LastName><ForeName>Fenna T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neimat</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurosurgery, University of Louisville School of Medicine, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durphy</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez-Zamora</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurology, Normal Fixel Institute for Neurological Disease, University of Florida, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilitsis</LastName><ForeName>Julie G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Now with Department of Neurosurgery, University of Arizona College of Medicine, Tucson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharen</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Now with Department of Neurosurgery, University of Louisville School of Medicine, Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Minnesota School of Medicine, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitek</LastName><ForeName>Jerrold L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota School of Medicine, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>INTREPID Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Starr reported receiving personal fees from Boston Scientific during the conduct of the study; grants from Boston Scientific and fellowship funding from Medtronic outside the submitted work; and holding a patent relevant to deep brain stimulation. Dr Hebb reported holding a patent relevant to deep brain stimulation. Dr Leichliter reported receiving personal fees from Neurocrine and Teva outside the submitted work. Dr Ostrem reported receiving grants from Neuroderm, Clearpoint, Medtronic, Merz, Medtronic, Amneal, AbbVie, Supernus, and Acadia; personal fees from Highland Instruments, Supernus, Insightec, Larimar, Aspen, and AcureX; and serving on the advisory boards for Larimar Therapeutics, Aspen Neuroscience, and AcureX outside the submitted work. Dr Verhagen Metman reported receiving funds for contracted research from Rush University during the conduct of the study and personal fees from Abbott and Medtronic outside the submitted work. Dr Siddiqui reported receiving grants, personal fees, and nonfinancial support from Boston Scientific Neuromodulation and AbbVie during the conduct of the study; grants from Sunovion Pharma, Biogen, Theravance Biopharma, Neuropoint Alliance/Michael J Fox Foundation, Impax Lab, and Sun Pharma outside the submitted work; and personal fees from Medtronic outside the submitted work. Dr Tatter reported receiving grants from Monteris Medical, Inc and Azurity Phamaceuticals outside the submitted work and serving on the advisory board of Boston Scientific. Dr Machado reported receiving grants from Abbott and Medtronic outside the submitted work; personal fees from Abbott; and holding distribution rights from Enspire DBS and Ceraxis outside the submitted work. Dr Tagliati reported receiving grants from Abbott and Medtronic outside the submitted work; personal fees from Abbott; and personal fees from Boston Scientific outside the submitted work. Dr Pahwa reported receiving research support from Abbott, AbbVie, Acadia, Allevion, Amneal, Amylyx, Appello, ASK Bio, Biogen, BioVie, Bluerock (Bayer), CalaHealth, Cerevance, Cerevel, Convatec, EIP, Fasikl, Genentech, Global Kinetics, Inhibikase, Intra-cellular Therapies, Insightec, Jazz, Keiferx, Kyowa, Lundbeck, Merz, Mitsubishi Tanabe, Michael J Fox Foundation, Neurocrine, Neuroderm, Neuron 23, Ono, Parkinson&#x2019;s Foundation, Praxis, PhotoPharmics, PSG, Regenxbio, Roche, Sage, Saluda, Scion, Sun Biopharma, Supernus, Teva, Theravance, TrueBinding, UCB, and Ventus outside the submitted work. Dr Lyons reported receiving personal fees from Fasikl, Sage, Jazz, and Parkinson's Foundation outside the submitted work. Dr Gross reported receiving personal fees from Boston Scientific during the conduct of the study; grants from Boston Scientific, Medtronic, and Abbott outside the submitted work; and personal fees from Boston Scientific, Medtronic, and Abbott outside the submitted work. Dr Pourfar reported receiving personal fees from Boston Scientific during the conduct of the study and personal fees from Boston Scientific outside the submitted work. Dr Mogilner reported receiving grants and personal fees from Boston Scientific during the conduct of the study. Dr Rosenow reported receiving research expenses and personal fees from Boston Scientific Neuromodulation during the conduct of the study and personal fees from Boston Scientific Neuromodulation outside the submitted work. Dr Neimat reported receiving personal fees from Medtronic, Abbott, and Boston Scientific outside the submitted work. Dr Ramirez-Zamora receiving reported serving on the advisory board of Boston Scientific during the conduct of the study; serving on the advisory board of Boston Scientific; and serving as a consultant for Medtronic outside the submitted work. Dr Pilitsis reported receiving grants and consulting fees from Boston Scientific during the conduct of the study; grants from Medtronic, Boston Scientific, Abbott, Focused Ultrasound Foundation, and the National Institutes of Health outside the submitted work; serving as the medical advisor for Aim Medical Robotics; and holding stock equity in Aim Medical Robotics. Dr Park reported receiving personal fees from Boston Scientific outside the submitted work; research support from the National Institutes of Health; personal fees from Zimmer Biomet, Smart Implant Systems/SynerFuse, Abbott, NeuroOne, Medtronic, and St. Jude Medical outside the submitted work; holding a patent for epilepsy treatment; and serving on the board for the Minnesota chapter of the American Parkinsons Disease Association. Dr Vitek reported receiving personal fees from Boston Scientific, nonfinancial support from Boston Scientific IPG's for nonhuman primate research, personal fees from Medtronic and Abbott during the conduct of the study; personal fees from Boston Scientific, Medtronic, Abbott, Surgical Information Sciences, Supernus, and Cala Health; and serving on the advisory board for Surgical Information Systems outside the submitted work. No other disclosures were reported. Dr Tr&#xf6;ster reported receiving personal fees and consulting fees from Boston Scientific during the conduct of the study. Dr ul Haq reported serving on the advisory board of Boston Scientific outside the submitted work; serving as an investigator on ongoing grants supported directly or indirectly by Boston Scientific; speaking honoraria from Michael J. Fox Foundation and Parkinson's Association of Southwest Florida; and serving on the Data Safety Monitoring board for a Tourette trial outside the submitted work. Dr Okun reported receiving grants from the National Institutes of Health, Tourette Association of America, Michael J Fox Foundation, and Parkinson&#x2019;s Foundation; royalties from Books4Patients; speaker fees from Movement Disorders Society and American Academy of Neurology; and continuing medical education courses and steering committees from Medscape, WebMD, MedEdicus, Academy of Learning Healthcare, Boston University CME, and Vanderbilt University outside the submitted work. Dr Foote reported receiving grants and personal fees from Medtronic and Boston Scientific, and grants from Abbott/St. Jude Medical and Functional Neuromodulation outside the submitted work. Dr Ponce reported receiving personal fees from Medtronic, Boston Scientific, and Abbott outside the submitted work. Dr Luca reported receiving research grants from Abbott and Boston Scientific outside the submitted work; consulting fees from Boston Scientific; speaking fees from Abbott, Boston Scientific, and Medtronic; and serving on the advisory boards for AbbVie, Supernus, and Amneal. Dr Jagid reported receiving grants from Boston Scientific, and grants and personal fees from Medtronic outside the submitted work. Dr Mandybur reported receiving grants and personal fees from Boston Scientific, Abbott, and Nevro outside the submitted work. Dr Phibbs reported receiving consulting fees from Medtronic and Boston Scientific.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>San Luciano</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galifianakis</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrock</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farris</LastName><ForeName>Sierra M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nazzarro</LastName><ForeName>Jules M</ForeName><Initials>JM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40952750</ArticleId><ArticleId IdType="pmc">PMC12439180</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2025.3373</ArticleId><ArticleId IdType="pii">2838886</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson&#x2019;s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurol. 2020;19(6):491-501. doi: 10.1016/S1474-4422(20)30108-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30108-3</ArticleId><ArticleId IdType="pubmed">32470421</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver FM, Follett K, Stern M, et al. ; CSP 468 Study Group . Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73. doi: 10.1001/jama.2008.929</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2008.929</ArticleId><ArticleId IdType="pmc">PMC2814800</ArticleId><ArticleId IdType="pubmed">19126811</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuschl G, Schade-Brittinger C, Krack P, et al. ; German Parkinson Study Group, Neurostimulation Section . A randomized trial of deep-brain stimulation for Parkinson&#x2019;s disease. N Engl J Med. 2006;355(9):896-908. doi: 10.1056/NEJMoa060281</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa060281</ArticleId><ArticleId IdType="pubmed">16943402</ArticleId></ArticleIdList></Reference><Reference><Citation>Okun MS, Gallo BV, Mandybur G, et al. ; SJM DBS Study Group . Subthalamic deep brain stimulation with a constant-current device in Parkinson&#x2019;s disease: an open-label randomised controlled trial. Lancet Neurol. 2012;11(2):140-149. doi: 10.1016/S1474-4422(11)70308-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70308-8</ArticleId><ArticleId IdType="pubmed">22239915</ArticleId></ArticleIdList></Reference><Reference><Citation>Defer GL, Widner H, Mari&#xe9; RM, R&#xe9;my P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson&#x2019;s disease (CAPSIT-PD). Mov Disord. 1999;14(4):572-584. doi: 10.1002/1531-8257(199907)14:4&lt;572::AID-MDS1005&gt;3.0.CO;2-C</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8257(199907)14:4&lt;572::AID-MDS1005&gt;3.0.CO;2-C</ArticleId><ArticleId IdType="pubmed">10435493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamani C, Richter E, Schwalb JM, Lozano AM. Bilateral subthalamic nucleus stimulation for Parkinson&#x2019;s disease: a systematic review of the clinical literature. Neurosurgery. 2005;56(6):1313-1321. doi: 10.1227/01.NEU.0000159714.28232.C4</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/01.NEU.0000159714.28232.C4</ArticleId><ArticleId IdType="pubmed">15918948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahwa R, Factor SA, Lyons KE, et al. ; Quality Standards Subcommittee of the American Academy of Neurology . Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995. doi: 10.1212/01.wnl.0000215250.82576.87</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000215250.82576.87</ArticleId><ArticleId IdType="pubmed">16606909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(S14)(suppl 14):S290-S304. doi: 10.1002/mds.20962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20962</ArticleId><ArticleId IdType="pubmed">16892449</ArticleId></ArticleIdList></Reference><Reference><Citation>Follett KA, Weaver FM, Stern M, et al. ; CSP 468 Study Group . Pallidal versus subthalamic deep-brain stimulation for Parkinson&#x2019;s disease. N Engl J Med. 2010;362(22):2077-2091. doi: 10.1056/NEJMoa0907083</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0907083</ArticleId><ArticleId IdType="pubmed">20519680</ArticleId></ArticleIdList></Reference><Reference><Citation>Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson&#x2019;s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37-44. doi: 10.1016/S1474-4422(12)70264-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70264-8</ArticleId><ArticleId IdType="pubmed">23168021</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuepbach WMM, Rau J, Knudsen K, et al. ; EARLYSTIM Study Group . Neurostimulation for Parkinson&#x2019;s disease with early motor complications. N Engl J Med. 2013;368(7):610-622. doi: 10.1056/NEJMoa1205158</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1205158</ArticleId><ArticleId IdType="pubmed">23406026</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A, Gill S, Varma T, et al. ; PD SURG Collaborative Group . Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson&#x2019;s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581-591. doi: 10.1016/S1474-4422(10)70093-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70093-4</ArticleId><ArticleId IdType="pmc">PMC2874872</ArticleId><ArticleId IdType="pubmed">20434403</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson&#x2019;s progression markers initiative cohort. Mov Disord Clin Pract. 2018;5(1):47-53. doi: 10.1002/mdc3.12553</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.12553</ArticleId><ArticleId IdType="pmc">PMC5898442</ArticleId><ArticleId IdType="pubmed">29662921</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011;68(12):1550-1556. doi: 10.1001/archneurol.2011.182</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.182</ArticleId><ArticleId IdType="pubmed">21825213</ArticleId></ArticleIdList></Reference><Reference><Citation>Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson&#x2019;s disease. N Engl J Med. 2003;349(20):1925-1934. doi: 10.1056/NEJMoa035275</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa035275</ArticleId><ArticleId IdType="pubmed">14614167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson&#x2019;s disease: five year follow-up. J Neurol. 2009;256(2):225-233. doi: 10.1007/s00415-009-0076-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0076-2</ArticleId><ArticleId IdType="pubmed">19242649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson&#x2019;s disease 8 years after subthalamic implants. Brain. 2010;133(9):2664-2676. doi: 10.1093/brain/awq221</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq221</ArticleId><ArticleId IdType="pubmed">20802207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzone MG, Fasano A, Daniele A, et al. Long-term outcome of subthalamic nucleus DBS in Parkinson&#x2019;s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord. 2014;20(4):376-381. doi: 10.1016/j.parkreldis.2014.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2014.01.012</ArticleId><ArticleId IdType="pubmed">24508574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hacker ML, Tonascia J, Turchan M, et al. Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2015;21(10):1177-1183. doi: 10.1016/j.parkreldis.2015.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.08.008</ArticleId><ArticleId IdType="pubmed">26306000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange F, Steigerwald F, Malzacher T, et al. Reduced programming time and strong symptom control even in chronic course through imaging-based DBS programming. Front Neurol. 2021;12:785529. doi: 10.3389/fneur.2021.785529</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.785529</ArticleId><ArticleId IdType="pmc">PMC8606823</ArticleId><ArticleId IdType="pubmed">34819915</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres V, Del Giudice K, Rold&#xe1;n P, et al. Image-guided programming deep brain stimulation improves clinical outcomes in patients with Parkinson&#x2019;s disease. NPJ Parkinsons Dis. 2024;10(1):29. doi: 10.1038/s41531-024-00639-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-024-00639-9</ArticleId><ArticleId IdType="pmc">PMC10821897</ArticleId><ArticleId IdType="pubmed">38280901</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn EJ, Blumenfeld Z, Velisar A, et al. Beta oscillations in freely moving Parkinson&#x2019;s subjects are attenuated during deep brain stimulation. Mov Disord. 2015;30(13):1750-1758. doi: 10.1002/mds.26376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26376</ArticleId><ArticleId IdType="pubmed">26360123</ArticleId></ArticleIdList></Reference><Reference><Citation>Oehrn CR, Cernera S, Hammer LH, et al. Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson&#x2019;s disease: a blinded randomized feasibility trial. Nat Med. 2024;30(11):3345-3356. doi: 10.1038/s41591-024-03196-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03196-z</ArticleId><ArticleId IdType="pmc">PMC11826929</ArticleId><ArticleId IdType="pubmed">39160351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>